Pharmaceutical Executive March 2016

March 2016 | Volume 36, Issue 3
From the Editor
With the emerging industry commitment to publicly disclose research and clinical trial results, two pivotal issues come to mind, writes William Looney.
Columns
As new ICH GCP draft guidelines now require root cause analysis, novel methods for risk analysis and triage must be adopted in drug development, writes Clara Heering.
More generics and biosimilars may generate competition — but FDA opposes broad compounding.
Europe’s contrasting views on rare disease drugs — one bashing pricing abuses, the other extolling their public health virtues — could ultimately leave these products out in the cold.
Features
Positioning for success in biopharma requires a self-critical analysis of the risk and rewards among four categories of value differentiation. The key question: How do you define yourself against the competition?
A new wave of technologies supported by innovative business models is transforming the vaccine landscape — and raising the bar on performance. Casey McDonald reports.
Can novel drug delivery technologies offering options beyond the traditional tablet or syringe transform the therapeutic experience for patients?
Special Sponsored Section
By Pharmaceutical Executive Editors
The Dutch healthcare system, dubbed today as a “laboratory for change,” is in the midst of reinventing itself around collaborations with industry and government in such areas as market and patient access, transparency, cost-effectiveness, and process innovation.
native1_300x100
lorem ipsum